From pro-prostate specific antigen, [-2]pro-prostate specific antigen to Beckman Coulter phi: The evolution of new biomarkers for early detection of prostatic carcinoma

Chinese Medical Journal

Volumn 125, Issue 9, 2012, Pages 1643-1649

  Zhang, Ming Zhi ^a   Lu, Yi Ping ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Enzyme precursors; Prostate cancer; Prostate specific antigen; Tumor markers

Indexed keywords

ENZYME PRECURSOR; ISOENZYME; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

AREA UNDER THE CURVE; ARTICLE; HUMAN; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; PREDICTIVE VALUE; PROSTATE BIOPSY; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; WESTERN BLOTTING;

HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84863199477     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.09.022     Document Type: Article

References (44)

1. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317: 909-916.
2. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156-1161.
3. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991; 145: 907-923.
4. Labrie F, Dupont A, Suburu R, Cusan L, Tremblay M, Gomez JL, et al. Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol 1992; 147: 846-852.
5. Berger NS. Prostate cancer: screening and early detection update. Semin Oncol Nurs 1993; 9: 180-183.
6. Hernandez J, Thompson IM. Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer 2004; 101: 894-904.
7. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Eng J Med 2004; 350: 2239-2246.
8. Stephan C, Jung K, Lein M, Diamandis EP. PSA and other tissue kallikreins for prostate cancer detection. Eur J Cancer 2007; 43: 1918-1926.
9. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 2004; 172: 1297-1301.
10. Lilja H, Christensson A, Dahlén U, Matikainen MT, Nilsson O, Pettersson K, et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem 1991; 37: 1618-1625.
11. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991; 51: 222-226.
12. Zhang WM, Leinonen J, Kalkkinen N, Dowell B, Stenman UH. Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fluid. Clin Chem 1995; 41: 1567-1573.
13. Christensson A, Björk T, Nilsson O, Dahlén U, Matikainen MT, Cockett AT, et al. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993; 150: 100-105.
14. Zhang WM, Finne P, Leinonen J, Vesalainen S, Nordling S, Rannikko S, et al. Characterization and immunological determination of the complex between prostate-specific antigen and alpha2-macroglobulin. Clin Chem 1998; 44: 2471-2479.
15. Zhang WM, Finne P, Leinonen J, Vesalainen S, Nordling S, Stenman UH. Measurement of the complex between prostate-specific antigen and alpha1-protease inhibitor in serum. Clin Chem 1999; 45: 814-821.
16. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998; 279: 1542-1547.
17. Uemura H, Nakamura M, Hasumi H, Sugiura S, Fujinami K, Miyoshi Y, et al. Effectiveness of percent free prostate specific antigen as a predictor of prostate cancer detection on repeat biopsy. Int J Urol 2004; 11: 494-500.
18. Mikolajczyk SD, Marks LS, Partin AW, Rittenhouse HG. Free prostate-specific antigen in serum is becoming more complex. Urology 2002; 59: 797-802.
19. Mikolajczyk SD, Grauer LS, Millar LS, Hill TM, Kumar A, Rittenhouse HG, et al. A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology 1997; 50: 710-714.
20. Mikolajczyk SD, Millar LS, Wang TJ, Rittenhouse HG, Marks LS, Song W, et al. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res 2000; 60: 756-759.
21. Peter J, Unverzagt C, Krogh TN, Vorm O, Hoesel W. Identification of precursor forms of free prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry. Cancer Res 2001; 61: 957-962.
22. Mikolajczyk SD, Millar LS, Marker KM, Wang TJ, Rittenhouse HG, Marks LS, et al. Seminal plasma contains "BPSA", a molecular form of prostate-specific antigen that is associated with benign prostatic hyperplasia. Prostate 2000; 45: 271-276.
23. Mikolajczyk SD, Millar LS, Wang TJ, Rittenhouse HG, Wolfert RL, Marks LS, et al. "BPSA", a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology 2000; 55: 41-45.
24. Linton HJ, Marks LS, Millar LS, Knott CL, Rittenhouse HG, Mikolajczyk SD. Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease. Clin Chem 2003; 49: 253-259.
25. Colette Jolivet-Reynaud SM, Catherine O. Detection of prostate-specific antigen forms and other kallikreins in prostate cancer. Med Nucl 2008; 32: 24-30.
26. Kumar A, Mikolajczyk SD, Goel AS, Millar LS, Saedi MS. Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res 1997; 57: 3111-3114.
27. Takayama TK, Fujikawa K, Davie EW. Characterization of the precursor of prostate-specific antigen. Activation by trypsin and by human glandular kallikrein. J Biol Chem 1997; 272: 21582-21588.
28. Mikolajczyk SD, Marker KM, Millar LS, Kumar A, Saedi MS, Payne JK, et al. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res 2001; 61: 6958-6963.
29. Chan TY, Mikolajczyk SD, Lecksell K, Shue MJ, Rittenhouse HG, Partin AW, et al. Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen. Urology 2003; 62: 177-181.
30. Sokoll LJ, Chan DW, Mikolajczyk SD, Rittenhouse HG, Evans CL, Linton HJ, et al. Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total PSA range: preliminary analysis. Urology 2003; 61: 274-276.
31. Mikolajczyk SD, Catalona WJ, Evans CL, Linton HJ, Millar LS, Marker KM, et al. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem 2004; 50: 1017-10125.
32. Catalona WJ, Bartsch G, Rittenhouse HG, Evans CL, Linton HJ, Horninger W, et al. Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol 2004; 171: 2239-2244.
33. Khan MA, Sokoll LJ, Chan DW, Mangold LA, Mohr P, Mikolajczyk SD, et al. Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%. Urology 2004; 64: 1160-1164.
34. Sokoll LJ, Wang Y, Feng Z, Kagan J, Partin AW, Sanda MG, et al. [e2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. J Urol 2008; 180: 539-543.
35. Le BV, Griffin CR, Loeb S, Carvalhal GF, Kan D, Baumann NA, et al. [N2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. J Urol 2010; 183: 1355-1359.
36. Jansen FH, van Schaik RH, Kurstjens J, Horninger W, Klocker H, Bektic J, et al. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 2010; 183: e826.
37. Sokoll LJ, Sanda MG, Feng Z, Kagan J, Mizrahi IA, Broyles DL, et al. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev 2010; 19: 1193-1200.
38. Vincendeau S, Ramirez J, Durand X, Deligne E. The beckman coulter prostate health index (phi) improves diagnostic accuracy in prostate cancer detection. Eur Urol Suppl 2010; 9: 309.
39. Catalona WJ, Sanda MG, Wei JT. [32]proPSA in combination with PSA and free-PSA, using the beckman coulter access immunoassay systems improves prostate cancer detectionrelative to PSA and free PSA. A multi-center prospective clinical study. J Urol 2010; 183: 1847.
40. Ito KMM, Yamamoto T, Suzuki K. Diagnostic significance of psPSAand volume adjusted psa related indices in japanese men with total PSA in the 2.0 to 10.0 ng/ml range. J Urol 2010; 183: 1733.
41. Naya Y, Fritsche HA, Bhadkamkar VA, Mikolajczyk SD, Rittenhouse HG, Babaian RJ. Volume-based evaluation of serum assays for new prostate-specific antigen isoforms in the detection of prostate cancer. Urology 2004; 63: 492-498.
42. Naya Y, Fritsche HA, Bhadkamkar VA, Mikolajczyk SD, Rittenhouse HG, Babaian RJ. Evaluation of precursor prostate-specific antigen isoform ratios in the detection of prostate cancer. Urol Oncol 2005; 23: 16-21.
43. Kwiatkowski M, Reeker F. Importance of [47]proPSA form for early detection of prostate cancer within total PSA range 4-10 ng/ml. Euro Urol 2004; 3 Suppl: 126.
44. Lein M, Semjonow A, Graefen M, Kwiatkowski M, Abramjuk C, Stephan C, et al. A multicenter clinical trial on the use of (t5, 57) pro prostate specific antigen. J Urol 2005; 174: 2150-2153.